81 related articles for article (PubMed ID: 32761905)
21. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
22. T cell immunobiology and cytokine storm of COVID-19.
Luo XH; Zhu Y; Mao J; Du RC
Scand J Immunol; 2021 Mar; 93(3):e12989. PubMed ID: 33113222
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.
Asrani P; Hassan MI
Mol Cell Biochem; 2021 Feb; 476(2):675-687. PubMed ID: 33064288
[TBL] [Abstract][Full Text] [Related]
24. Characterization of METRNβ as a novel biomarker of Coronavirus disease 2019 severity and prognosis.
Gao X; Chan PK; Wong KC; Ng RW; Yeung AC; Lui GC; Ling L; Hui DS; Huang D; Wong CK
Front Immunol; 2023; 14():1111920. PubMed ID: 36798115
[TBL] [Abstract][Full Text] [Related]
25. Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients.
Maraia Z; Mazzoni T; Rocchi MBL; Feliciani D; Romani MC; Acciarri G; Rafaiani S; Mazzoni I
J Pers Med; 2022 Oct; 12(11):. PubMed ID: 36579506
[TBL] [Abstract][Full Text] [Related]
26. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.
Forchette L; Sebastian W; Liu T
Curr Med Sci; 2021 Dec; 41(6):1037-1051. PubMed ID: 34241776
[TBL] [Abstract][Full Text] [Related]
27. Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection.
Bozorgmehr N; Mashhouri S; Perez Rosero E; Xu L; Shahbaz S; Sligl W; Osman M; Kutsogiannis DJ; MacIntyre E; O'Neil CR; Elahi S
mBio; 2021 May; 12(3):. PubMed ID: 33947753
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial.
Faqihi F; Alharthy A; Abdulaziz S; Balhamar A; Alomari A; AlAseri Z; Tamim H; Alqahtani SA; Kutsogiannis DJ; Brindley PG; Karakitsos D; Memish ZA
Int J Antimicrob Agents; 2021 May; 57(5):106334. PubMed ID: 33838224
[TBL] [Abstract][Full Text] [Related]
29. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.
Mady A; Aletreby W; Abdulrahman B; Lhmdi M; Noor AM; Alqahtani SA; Soliman I; Alharthy A; Karakitsos D; Memish ZA
Ann Med Surg (Lond); 2020 Dec; 60():417-424. PubMed ID: 33169088
[TBL] [Abstract][Full Text] [Related]
30. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Yongzhi X
Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893
[TBL] [Abstract][Full Text] [Related]
31. COVID 19: in the eye of the cytokine storm.
Liuzzo G; Patrono C
Eur Heart J; 2021 Jan; 42(2):150-151. PubMed ID: 33462598
[No Abstract] [Full Text] [Related]
32. Comment on Hu et al: The cytokine storm and COVID-19.
Faqihi F; Alharthy A; Memish ZA; Karakitsos D
J Med Virol; 2021 Feb; 93(2):631-633. PubMed ID: 32761905
[No Abstract] [Full Text] [Related]
33. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
34. Response to: 'Correspondence on 'Preliminary predictive criteria for COVID-19 cytokine storm'' by Tampe
Caricchio R; Gallucci M; Dass C; Zhang X; Gallucci S; Fleece D; Bromberg M; Criner GJ
Ann Rheum Dis; 2023 Mar; 82(3):e72. PubMed ID: 33414184
[No Abstract] [Full Text] [Related]
35. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.
Jiang Y; Rubin L; Peng T; Liu L; Xing X; Lazarovici P; Zheng W
Int J Biol Sci; 2022; 18(2):459-472. PubMed ID: 35002503
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
